Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of combining Dato-DXd with rilvegostomig as an additional treatment compared to standard care in adults with high-risk muscle invasive urothelial carcinoma MIUC who have undergone radical surgery. This Phase III trial focuses on participants with residual disease at high risk of recurrence after surgery. The study aims to see if the new combination improves disease-free survival compared to current standard treatments. Participants are randomly assigned to one of three groups Arm 1 receives Dato-DXd plus rilvegostomig intravenously every three weeks for up to one year Arm 2 receives Dato-DXd alone on the same schedule Arm 3 receives standard care, which includes nivolumab, durvalumab, or a combination of enfortumab vedotin and pembrolizumab, given intravenously at intervals ranging from every two to four weeks for up to a year. Treatment duration and dosing can be adjusted based on tolerance and investigator assessment. During the trial, participants will have visits approximately every three weeks or as per standard care schedules, depending on their assigned group, for up to 12 months of treatment. Researchers will monitor disease recurrence and survival outcomes for up to 78 months from the first participants enrollment. Assessments include clinical evaluations and disease status monitoring to measure disease-free survival and overall survival. Participants will be followed closely to assess safety and effectiveness of the treatments over this extended period.
Actively Recruiting
Researchers are evaluating the new medicine PF-08634404 in combination with chemotherapy compared to the current standard treatment pembrolizumab with chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer NSCLC. The study includes adults with Stage IIIBIIIC or Stage IV squamous or non-squamous NSCLC who are not candidates for surgery or curative chemoradiotherapy and have not received prior treatment for advanced disease. Participants are assigned to two parts based on tumor type squamous NSCLC Part 1 or non-squamous NSCLC Part 2. Each participant is randomly assigned to receive either PF-08634404 or pembrolizumab with chemotherapy followed by maintenance therapy. Treatment is given through intravenous infusions in cycles, continuing as long as it is effective and safe. Different chemotherapy regimens are used depending on the tumor type. Throughout the study, participants attend regular visits for treatment and health monitoring. Cancer response is assessed every 6 weeks for the first 48 weeks and then every 12 weeks. Researchers will measure overall survival, progression-free survival, objective response rates, duration of response, adverse events, laboratory results, drug levels, immune response, and quality of life using questionnaires. The study lasts up to approximately 39 months with ongoing safety and effectiveness evaluations.
Actively Recruiting
Researchers are evaluating PF-08634404, a new medicine, in adults with Transformed Small Cell Lung Cancer T-SCLC, a rare and aggressive form of lung cancer that develops after other treatments stop working. The study aims to understand how well PF-08634404 works when given alone or combined with chemotherapy. Participants must be adults aged 18 or older, diagnosed with T-SCLC, and have not previously been treated for this cancer type except possibly one cycle of chemotherapy. Participants will receive PF-08634404 together with chemotherapy through intravenous infusions at clinical study sites. After completing this combination treatment, participants will continue receiving PF-08634404 alone as maintenance therapy. All treatment visits are conducted under medical supervision to monitor safety and response. During the study, participants will undergo various assessments including tumor measurements using RECIST criteria to evaluate response, laboratory tests to monitor organ function, and tracking of any side effects. Researchers will also measure how long responses last, progression-free survival, overall survival, and blood concentrations of PF-08634404. Safety monitoring will continue up to 90 days after treatment ends. The study lasts up to several years, with ongoing follow-up to assess outcomes.
Actively Recruiting
Researchers are evaluating the efficacy and safety of torvutatug samrotecan, alone or combined with bevacizumab, compared to standard of care as maintenance treatment for participants with platinum-sensitive relapsed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. This Phase III study aims to improve treatment options after relapse with a focus on progression-free survival. Participants are randomly assigned to receive either intravenous torvutatug samrotecan alone or with bevacizumab, or to observation or bevacizumab alone as the comparator. Those assigned to bevacizumab must have previously received at least three cycles of the drug combined with platinum-based chemotherapy during their induction phase. The study includes a 5-year follow-up to assess long-term outcomes. During the trial, participants will undergo regular monitoring including assessments of progression-free survival, overall survival, subsequent therapy use, quality of life, and adverse events graded by standard criteria. Archival tumor samples are collected for analysis, and participants will be followed for up to approximately five years to evaluate treatment effects and safety. The study is conducted by AstraZeneca and includes adult women with confirmed high-grade epithelial ovarian or related cancers.